US WorldMeds Buys Orbus to Pursue Eflornithine in Glioma
LOUISVILLE – October 28, 2026 -- US WorldMeds Ventures, LLC has acquired Orbus Therapeutics, Inc., adding a late-stage eflornithine program for recurrent Grade 3 astrocytoma. In a prespecified subset of the Phase 3 STELLAR study, patients with IDH-mutant disease reached median overall survival of 34.9 months, versus 23.5 months on lomustine alone.
US WorldMeds made an undisclosed upfront payment under a definitive merger agreement. Orbus is eligible for development, regulatory and sales-based milestone payments, plus tiered royalties on U.S. net sales. It is now a wholly owned subsidiary of US WorldMeds.
STELLAR missed its primary endpoint in the full study population
The 343-patient trial compared eflornithine plus lomustine with lomustine alone in recurrent Grade 3 astrocytoma, defined under the 2016 WHO classification. It showed no overall survival difference between arms in the intent-to-treat population, which was the primary endpoint.